DK1745040T3 - Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater - Google Patents

Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater

Info

Publication number
DK1745040T3
DK1745040T3 DK05707610.1T DK05707610T DK1745040T3 DK 1745040 T3 DK1745040 T3 DK 1745040T3 DK 05707610 T DK05707610 T DK 05707610T DK 1745040 T3 DK1745040 T3 DK 1745040T3
Authority
DK
Denmark
Prior art keywords
azabicyclo
dopamine
modulators
receptors
derivatives useful
Prior art date
Application number
DK05707610.1T
Other languages
English (en)
Inventor
Luca Arista
Giorgio Bonanomi
Anna Maria Capelli
Federica Damiani
Fabio Romano Di
Gabriella Gentile
Dieter Hamprecht
Fabrizio Micheli
Luca Tarsi
Giovanna Tedesco
Silvia Terreni
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1745040T3 publication Critical patent/DK1745040T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK05707610.1T 2004-02-23 2005-02-21 Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater DK1745040T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
PCT/EP2005/001940 WO2005080382A1 (en) 2004-02-23 2005-02-21 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
DK1745040T3 true DK1745040T3 (da) 2010-04-12

Family

ID=34890800

Family Applications (3)

Application Number Title Priority Date Filing Date
DK08169935.7T DK2060570T3 (da) 2004-02-23 2005-02-21 Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
DK08169934.0T DK2070922T3 (da) 2004-02-23 2005-02-21 Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexan-derivater
DK05707610.1T DK1745040T3 (da) 2004-02-23 2005-02-21 Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK08169935.7T DK2060570T3 (da) 2004-02-23 2005-02-21 Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
DK08169934.0T DK2070922T3 (da) 2004-02-23 2005-02-21 Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexan-derivater

Country Status (26)

Country Link
US (3) US7855298B2 (da)
EP (3) EP2070922B1 (da)
JP (1) JP4960217B2 (da)
KR (1) KR101143718B1 (da)
CN (1) CN1946714B (da)
AR (1) AR047890A1 (da)
AT (3) ATE520686T1 (da)
AU (2) AU2005215918C1 (da)
BR (1) BRPI0507945A (da)
CA (1) CA2557115C (da)
CY (3) CY1109854T1 (da)
DE (1) DE602005018190D1 (da)
DK (3) DK2060570T3 (da)
ES (2) ES2380990T3 (da)
HK (1) HK1103016A1 (da)
HR (3) HRP20100114T1 (da)
IL (1) IL177184A0 (da)
MA (1) MA28438B1 (da)
NO (1) NO20064309L (da)
PE (1) PE20051173A1 (da)
PL (3) PL2070922T3 (da)
PT (3) PT1745040E (da)
RU (1) RU2434011C2 (da)
SI (3) SI2070922T1 (da)
TW (1) TW200538113A (da)
WO (1) WO2005080382A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538113A (en) * 2004-02-23 2005-12-01 Glaxo Group Ltd Compounds
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ATE484502T1 (de) 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0512099D0 (en) 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
EP2719384B1 (en) * 2005-07-27 2018-08-08 Otsuka America Pharmaceutical, Inc. Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
JP5189074B2 (ja) 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
JP5189076B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0607899D0 (en) * 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
US8178333B2 (en) 2008-06-24 2012-05-15 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US8906913B2 (en) * 2009-06-26 2014-12-09 Panacea Biotec Limited Azabicyclohexanes
WO2015070253A1 (en) * 2013-11-11 2015-05-14 Euthymics Bioscience, Inc. Novel methods
AU2016303558B2 (en) 2015-08-05 2020-08-06 Indivior Uk Limited Dopamine D3 receptor antagonists having a bicyclo moiety
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
JP2023535279A (ja) 2020-06-22 2023-08-17 コーセプト セラピューティクス， インコーポレイテッド ４級インダゾールグルココルチコイド受容体アンタゴニスト
US20230242514A1 (en) * 2021-12-21 2023-08-03 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022228A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
PL362992A1 (en) 2000-11-14 2004-11-15 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
SI1440059T1 (sl) * 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
KR20050033070A (ko) * 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
TW200538113A (en) * 2004-02-23 2005-12-01 Glaxo Group Ltd Compounds
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ATE484502T1 (de) 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
JP5189074B2 (ja) 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
PL2070922T3 (pl) 2012-01-31
CN1946714A (zh) 2007-04-11
US7855298B2 (en) 2010-12-21
US20070142438A1 (en) 2007-06-21
DK2060570T3 (da) 2012-04-30
AU2005215918B2 (en) 2009-06-11
AU2005215918A1 (en) 2005-09-01
WO2005080382A1 (en) 2005-09-01
DK2070922T3 (da) 2011-11-28
JP2007523208A (ja) 2007-08-16
ES2337590T3 (es) 2010-04-27
CY1109854T1 (el) 2014-09-10
PT2060570E (pt) 2012-05-07
ATE451364T1 (de) 2009-12-15
IL177184A0 (en) 2006-12-10
EP1745040B1 (en) 2009-12-09
HRP20120281T1 (hr) 2012-04-30
HRP20100114T1 (hr) 2010-04-30
SI2060570T1 (sl) 2012-05-31
HRP20110781T1 (hr) 2011-11-30
PT2070922E (pt) 2011-11-24
AU2009212887A1 (en) 2009-09-24
CN1946714B (zh) 2011-06-15
EP2060570B1 (en) 2012-01-25
EP1745040B9 (en) 2010-06-02
ATE520686T1 (de) 2011-09-15
US20100152195A1 (en) 2010-06-17
CA2557115C (en) 2012-10-02
JP4960217B2 (ja) 2012-06-27
TW200538113A (en) 2005-12-01
RU2006133909A (ru) 2008-03-27
US8263782B2 (en) 2012-09-11
CA2557115A1 (en) 2005-09-01
CY1112011T1 (el) 2015-11-04
NO20064309L (no) 2006-11-23
KR101143718B1 (ko) 2012-07-05
EP1745040A1 (en) 2007-01-24
HK1103016A1 (en) 2007-12-14
SI1745040T1 (sl) 2010-04-30
AR047890A1 (es) 2006-03-01
EP2060570A3 (en) 2009-06-03
BRPI0507945A (pt) 2007-07-24
US8283474B2 (en) 2012-10-09
ATE542816T1 (de) 2012-02-15
PE20051173A1 (es) 2006-02-14
MA28438B1 (fr) 2007-02-01
PL1745040T3 (pl) 2010-05-31
PL2060570T3 (pl) 2012-06-29
RU2434011C2 (ru) 2011-11-20
EP2070922B1 (en) 2011-08-17
EP2070922A1 (en) 2009-06-17
AU2005215918C1 (en) 2010-01-21
US20100160336A1 (en) 2010-06-24
SI2070922T1 (sl) 2011-12-30
CY1113029T1 (el) 2016-04-13
ES2380990T3 (es) 2012-05-22
EP2060570A2 (en) 2009-05-20
DE602005018190D1 (de) 2010-01-21
KR20060127991A (ko) 2006-12-13
PT1745040E (pt) 2010-03-08

Similar Documents

Publication Publication Date Title
DK1745040T3 (da) Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK1668014T3 (da) Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
DK1735286T3 (da) Tetrahydroindazoler som cannabinoidmodulatorer
DK1756096T3 (da) Indolylderivater som lever-X-receptormodulatorer
AP2314A (en) 3- 4-heteroarylcyclohexylamino cyclopentanecarboxamides as modulators of chemokine receptors.
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
IL192327A0 (en) Modulators of muscarinic receptors
DK1817309T3 (da) Acetamidforbindelser som fungicider
DE602004028229D1 (de) Prostaglandin analoge als ep4 rezeptor agonisten
ZA200802007B (en) 1,3-disubstituted indole derivatives for use as PPAR modulators
IL194385A0 (en) Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
DK1735304T3 (da) Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
DK1891075T3 (da) Tricykliske spiroderivater som CRTH2-modulatorer
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1761497T3 (da) Azadecalinglucocorticoidreceptormodulatorer
DK1778243T3 (da) Substituerede azepinderivater som serotoninreceptormodulatorer
ZA200606661B (en) Modulation of peroxisome proliferation-activated receptors
DK1928821T3 (da) Carboxamidderivater som muscarinreceptorantagonister
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
MA28361A1 (fr) Modulateurs des recepteurs d'androgenes
DK2099784T3 (da) 1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-on som cb1-receptor-modulatorer
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer